MedPath

Implementation of Bright Light Therapy ID

Recruiting
Conditions
Depressive Symptoms
Interventions
Other: Bright light therapy
Registration Number
NCT06215235
Lead Sponsor
Erasmus Medical Center
Brief Summary

Many adults with intellectual disabilities (ID) have depressive symptoms, which negatively impact their quality of life. A lot of of the non-medicinal forms of treatment are not or hardly suitable for people with ID. Bright light therapy (BLT) seems to be a good option. Earlier research has shown that BLT is applicable in this group and seems promising in terms of reducing depressive symptoms, without serious side effects.

In part 1 of this project we investigate the implementation of BLT at Amarant. We will take the lessons learned into part 2 of this project: the implementation of BLT at Abrona. We will evaluate this process and the outcomes.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
105
Inclusion Criteria
  • Involved in the implementation of BLT (staff) OR
  • Involved in the prescription or application of BLT (staff/relatives) OR
  • receiving BLT for their depressive symptoms (patients with ID)
  • 18 years or older
  • informed consent
Exclusion Criteria
  • n/a

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Persons involved in BLTBright light therapyPersons with ID and staff who are involved in BLT. Either by receiving BLT, or by prescribing or facitating BLT.
Primary Outcome Measures
NameTimeMethod
Determinantsthree times during study, 3-4 months in between

Barriers and facilitators to BLT, measured by interviews using the Consolidated Framework for Implementation Research (CFIR, Damschroder et al., 2009)

acceptabilitythree times during study, 3-4 months in between

Acceptability (Proctor et al., 2011) is the perception among implementation stakeholders that a given treatment, service, practice, or innovation is agreeable, palatable, or satisfactory. This will be measured by interviews.

appropriatenessthree times during study, 3-4 months in between

Appropriateness (Proctor et al., 2011) is the perceived fit, relevance, or compatibility of the innovation or evidence based practice for a given practice setting, provider, or consumer; and/or perceived fit of the innovation to address a particular issue or problem. This will be measured by interviews.

feasibility of the interventionthree times during study, 3-4 months in between

Feasibility (Proctor et al., 2011) is defined as the extent to which a new treatment, or an innovation, can be successfully used or carried out within a given agency or setting. This will be measured by interviews.

fidelitythree times during study, 3-4 months in between

Fidelity (Proctor et al., 2011) is defined as the degree to which an intervention was implemented as it was prescribed in the original protocol or as it was intended by the program developers. This will be measured by interviews and by case report study.

strategiesthree times during study, 3-4 months in between

Implementation strategies are methods to enhance the adoption, implementation and sustainability of a policy or intervention. This will be studied with interview data and logs.

Secondary Outcome Measures
NameTimeMethod
Depressive symptoms1 year

Depressive symptoms measured by the Anxiety, Depression, and Mood Scale (ADAMS, Hermans et al., 2008). It contains 28 items, each can be scored 0 to 3. Minimum score 0 and maximum score 84 and higher scores mean worse outcome.

Behaviour1 year

Behaviour that could be linked to depressive symptoms measured by the Aberrant Behaviour Checklist (ABC, Aman et al., 1985). It contains 58 items, each can be scored 0 to 3. Minimum score 0 and maximum score 174. Higher score means worse outcome.

Trial Locations

Locations (1)

ErasmusMC

🇳🇱

Rotterdam, Netherlands

© Copyright 2025. All Rights Reserved by MedPath